Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Delia Silverio"'
Autor:
Constantine E. Kosmas, Delia Silverio, Andreas Sourlas, Frederick N. Campos, Peter D. Montan, Eliscer Guzman
Publikováno v:
European Medical Journal Cardiology, Vol 7, Iss 1, Pp 89-97 (2019)
Calcific aortic valve stenosis is the most common valve disease in the elderly population and is associated with significant morbidity and mortality. This condition is characterised by gradual fibrosis, thickening, and calcification of the affected l
Externí odkaz:
https://doaj.org/article/b76b7bf26fa94e9baa7e484d4682ce1d
Autor:
Constantine E Kosmas, Andreas Sourlas, Gordon Mallarkey, Delia Silverio, Domingo Y Ynoa, Peter D Montan, Eliscer Guzman, Mario J Garcia
Publikováno v:
Drugs in Context, Vol 8, Pp 1-11 (2019)
Cardiovascular disease (CVD) has consistently been the leading cause of death worldwide. Several clinical and epidemiological studies have demonstrated that an elevated plasma concentration of lipoprotein (a) [Lp(a)] is a causative and independent ma
Externí odkaz:
https://doaj.org/article/d2fd463cf3c446d8a15c8f7b84d1fd8d
Autor:
Constantine E Kosmas, Delia Silverio, Andreas Sourlas, Frank Garcia, Peter D Montan, Eliscer Guzman
Publikováno v:
Drugs in Context, Vol 7, Pp 1-7 (2018)
Lipid-lowering therapy is used very commonly nowadays not only for the optimization of the lipid profile but also to reduce cardiovascular risk. However, some studies have linked the use of certain lipid-lowering agents with an increased risk for imp
Externí odkaz:
https://doaj.org/article/0359c64300c7488ea0c4f4832ef66955
Autor:
Constantine E Kosmas, Delia Silverio, Andreas Sourlas, Frank Garcia, Peter D Montan, Eliscer Guzman
Publikováno v:
Drugs in Context, Vol 7, Pp 1-11 (2018)
There is extensive evidence demonstrating that there is a clear inverse correlation between plasma high density lipoprotein cholesterol (HDL-C) concentration and cardiovascular disease (CVD). On the other hand, there is also extensive evidence that H
Externí odkaz:
https://doaj.org/article/8e89a36a74de43adadde56c693ba7d16
Autor:
Constantine E Kosmas, Delia Silverio, Christiana Tsomidou, Maria D Salcedo, Peter D Montan, Eliscer Guzman
Publikováno v:
Clinical Medicine Insights: Endocrinology and Diabetes, Vol 11 (2018)
There is extensive evidence showing that insulin resistance (IR) is associated with chronic low-grade inflammation. Furthermore, IR has been shown to increase the risk for cardiovascular disease (CVD), even in nondiabetic patients, and is currently c
Externí odkaz:
https://doaj.org/article/a3e786e2596843c3b626e79cfa466c18
Autor:
Constantine E. Kosmas, Alba Muñoz Estrella, Andreas Sourlas, Delia Silverio, Elizabeth Hilario, Peter D. Montan, Eliscer Guzman
Publikováno v:
Diseases, Vol 6, Iss 3, p 63 (2018)
The discovery of proprotein convertase subtilisin-kexin type 9 (PCSK9), a serine protease which binds to the low-density lipoprotein (LDL) receptors and targets the receptors for lysosomal degradation, offered an additional route through which plasma
Externí odkaz:
https://doaj.org/article/8bb8b4f2a7f54ef3bc89fb867ddf5ecb
Publikováno v:
World Journal of Cardiology
Cardiovascular disease (CVD) remains a major cause of morbidity and mortality worldwide. Currently, it is well established that dyslipidemia is one of the major risk factors leading to the development of atherosclerosis and CVD. Statins remain the st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc3a71f62cb26504d615decc9b89d288
http://europepmc.org/articles/PMC6885448
http://europepmc.org/articles/PMC6885448
Autor:
Frank Garcia, Andreas Sourlas, Eliscer Guzman, Delia Silverio, Constantine E Kosmas, Peter D Montan
Publikováno v:
Drugs in Context, Vol 7, Pp 1-7 (2018)
Drugs in Context
Drugs in Context
Lipid-lowering therapy is used very commonly nowadays not only for the optimization of the lipid profile but also to reduce cardiovascular risk. However, some studies have linked the use of certain lipid-lowering agents with an increased risk for imp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12661ed200354194195ab04a39142ba0
https://www.drugsincontext.com/impact-lipid-lowering-therapy-on-glycemic-control-risk-new-onset-diabetes
https://www.drugsincontext.com/impact-lipid-lowering-therapy-on-glycemic-control-risk-new-onset-diabetes
Publikováno v:
Patient preference and adherence
Evolocumab is a PCSK9 inhibitor which is administered subcutaneously, and when added to statin therapy it has been shown to cause a significant incremental LDL-C reduction, leading to a reduction of cardiovascular risk. Evolocumab has a favorable sid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d47fe58f77ec7e77b4d7d7663848a436
http://europepmc.org/articles/PMC6214408
http://europepmc.org/articles/PMC6214408
Autor:
Andreas Sourlas, Peter D Montan, Constantine E Kosmas, Delia Silverio, Eliscer Guzman, Frank Garcia
Publikováno v:
Drugs in Context, Vol 7, Pp 1-11 (2018)
Drugs in Context
Drugs in Context
There is extensive evidence demonstrating that there is a clear inverse correlation between plasma high density lipoprotein cholesterol (HDL-C) concentration and cardiovascular disease (CVD). On the other hand, there is also extensive evidence that H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70dda45a53fb5f6964a88c28d6720588
https://www.drugsincontext.com/primary-genetic-disorders-affecting-high-density-lipoprotein-hdl
https://www.drugsincontext.com/primary-genetic-disorders-affecting-high-density-lipoprotein-hdl